Apollomics (APLM) Research Hub

Apollomics (APLM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.9 USD (-8.88%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.46, market cap 0.02B. This hub links to the full technical, earnings and options research available for APLM.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close19.9 USD (-8.88%)
52-week range12.88 USD – 28.29 USD
Trend regimeRange
14-day RSI33.6 (Bearish)
Trailing P/E-2.46
Market cap0.02B
Dividend yield0.00%
Next earnings2026-09-24

Available research for APLM

Earnings

APLM earnings date and last-quarter result: next report 2026-09-24, last quarter miss, P/E -2.46. Updated 2026-07-23.

Options: Covered Call

Covered Call on APLM: how it works, illustrative setup around the real 19.9 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on APLM: how it works, illustrative setup around the real 19.9 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on APLM: how it works, illustrative setup around the real 19.9 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

APLM technical analysis: range, last 19.9 USD, RSI 33.6, 52w range 12.88 USD–28.29 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is APLM in?

Apollomics (APLM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is APLM in an uptrend or downtrend?

As of 2026-10-26, APLM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is APLM's trailing P/E ratio?

APLM's trailing P/E is -2.46, with a market cap of 0.02B. See the earnings research page for full valuation detail.

When does APLM next report earnings?

APLM is next scheduled to report earnings on 2026-09-24.